SystImmune Inc.
The objective of the study is to evaluate the safety and tolerability of SI-B037 in participants with locally advanced or metastatic solid tumors.
This study is an open-label, multicenter, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary efficacy of SI-B037 in participants with locally advanced or metastatic solid tumors.
Inclusion Criteria: * Signed the informed consent form voluntarily and agreed to follow the trial requirements. * Male or Female Age ≥18 years. * Has a life expectancy of ≥3 months. * Subjects with documented locally advanced or metastatic solid tumor(s) not amenable to curative surgery or radiation and have received at least 1 line of standard therapy in the metastatic setting. * At least 1 measurable lesion based on RECIST 1.1 * Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1. * Toxicity of previous antitumor therapy has returned to level ≤1 as defined by NC…
SI-B037 will be administered by intravenous (IV) infusion on Day 1 every 3 weeks